modelB01AF51
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | RivaroxabanAndAcetylsalicylicAcid | |
| ATC code: | B01AF51 | route: | oral |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 50 | L |
| clearance: | 10 | L/h |
| other parameters in model implementation | ||
Combination of rivaroxaban, a direct oral factor Xa inhibitor anticoagulant, and acetylsalicylic acid (aspirin), an antiplatelet agent used to reduce blood clot formation. This drug combination is approved in some countries for prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Pharmacokinetics
Estimated pharmacokinetic parameters for the fixed-dose combination in healthy adults, based on individual PK profiles of rivaroxaban and acetylsalicylic acid. No direct clinical publication reporting validated population PK parameters for the combination under ATC B01AF51 found.
References
Pincus, KJ, & Hynicka, LM (2013). Prophylaxis of thromboembolic events in patients with nephrotic syndrome. The Annals of pharmacotherapy 47(5) 725–734. DOI:10.1345/aph.1R530 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23613095
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)